Subscribe To
Springworks therapeutics reports third quarter 2023 financial results and recent business highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for Novembe...
November 2, 2023, 10:30 am
Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting
– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...
November 1, 2023, 10:30 am
Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 asco annual meeting
– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools – –...
May 25, 2023, 9:05 pm
Springworks therapeutics announces new england journal of medicine publication of phase 3 defi trial evaluating nirogacestat in adults with desmoid tumors
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Dru...
March 8, 2023, 10:05 pm
Springworks therapeutics completes submission of new drug application to the fda for nirogacestat for the treatment of adults with desmoid tumors
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused ...
December 27, 2022, 11:30 am
Springworks therapeutics shares jump on hc wainwright bullish pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for ...
June 13, 2022, 9:14 am
Springworks therapeutics to present progress across the company's targeted oncology portfolio at virtual r&d day
-- NDA filing for Nirogacestat in desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Onco...
June 10, 2022, 6:30 am
Springworks (swtx) down despite desmoid tumors study meeting goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing ...
May 25, 2022, 1:48 pm
Springworks therapeutics: rating buy ahead of mid-year data releases
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with ...
May 2, 2022, 5:42 pm